Abstract:Cerebral small vessel injury, including loss of endothelial tight junctions, endothelial dysfunction, and blood-brain barrier breakdown, is an early and typical pathology for Alzheimer disease, cerebral amyloid angiopathy, and hypertension-related cerebral small vessel disease. Whether there is a common mechanism contributing to these cerebrovascular alterations remains unclear. Studies have shown an elevation of BACE1 (β-site amyloid precursor protein cleaving enzyme 1) in cerebral vessels from cerebral amyloid angiopathy or Alzheimer disease patients, suggesting that vascular BACE1 may involve in cerebral small vessel injury. To understand the contribution of vascular BACE1 to cerebrovascular impairments, we combined cellular and molecular techniques, mass spectrometry, immunostaining approaches, and functional testing to elucidate the potential pathological mechanisms. We observe a 3.71-fold increase in BACE1 expression in the cerebral microvessels from patients with hypertension. Importantly, we discover that an endothelial tight junction protein, occludin, is a completely new substrate for endothelial BACE1. BACE1 cleaves occludin with full-length occludin reductions and occludin fragment productions. An excessive cleavage by elevated BACE1 induces membranal accumulation of caveolin-1 and subsequent caveolin-1-mediated endocytosis, resulting in lysosomal degradation of other tight junction proteins. Meanwhile, membranal caveolin-1 increases the binding to eNOS (endothelial nitric oxide synthase), together with raised circulating Aβ (β-amyloid peptides) produced by elevated BACE1, leading to an attenuation of eNOS activity and resultant endothelial dysfunction. Furthermore, the initial endothelial damage provokes chronic reduction of cerebral blood flow, blood-brain barrier leakage, microbleeds, tau hyperphosphorylation, synaptic loss, and cognitive impairment in endothelial-specific BACE1 transgenic mice. Conversely, inhibition of aberrant BACE1 activity ameliorates tight junction loss, endothelial dysfunction, and memory deficits. Our findings establish a novel and direct relationship between endothelial BACE1 and cerebral small vessel damage, indicating that abnormal elevation of endothelial BACE1 is a new mechanism for cerebral small vessel disease pathogenesis. Download figure Download PowerPoint

Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?

O4‐02‐01: A Novel Role of Beta‐secretase1 (BACE1) in the Pathogenesis of Cerebral Amyloid Angiopathy (CAA)

A Novel Role Of Beta-Secretase 1 (Bace1) In The Pathogenesis Of Cerebral Amyloid Angiopathy (Caa)

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

The Role of Amyloid Beta Clearance in Cerebral Amyloid Angiopathy: More Potential Therapeutic Targets

Non-neuronal and Neuronal BACE1 Elevation in Association with Angiopathic and Leptomeningeal Β-Amyloid Deposition in the Human Brain

Discovery of Novel, Potent BACE Inhibitors with Central Activity for the Treatment of Alzheimer's Disease

BACE1 controls synaptic function through modulating release of synaptic vesicles

Abstract WP555: Plasma Beta-Secretase 1 in Cerebral Amyloid Angiopathy

Endothelial BACE1 Impairs Cerebral Small Vessels via Tight Junctions and eNOS

Occludin Deficiency with BACE1 Elevation in Cerebral Amyloid Angiopathy

BACE Inhibitor Clinical Trials for Alzheimer's Disease

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

Transcriptomic Profile of Blood–Brain Barrier Remodeling in Cerebral Amyloid Angiopathy

Intracisternal Injection of Beta-Amyloid Seeds Promotes Cerebral Amyloid Angiopathy

BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives

BACE1 Inhibition Utilizing Organic Compounds Holds Promise as a Potential Treatment for Alzheimer's and Parkinson's Diseases

Multivalent Targeting of Blood-Brain Barrier LRP1 for Neurovascular Recovery Therapy for Alzheimer s Disease

BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model.

Associations of CSF BACE1 with Amyloid Pathology, Neurodegeneration, and Cognition in Alzheimer’s Disease